Cinacalcet improves endothelial dysfunction and cardiac hypertrophy in patients on hemodialysis with secondary hyperparathyroidism

Nephron - Clinical Practice

Volumn 122, Issue 1-2, 2013, Pages 1-8

  Choi, Sun Ryoung ^a   Lim, Ji Hee ^b   Kim, Min Young ^b   Hong, Yu Ah ^b   Chung, Byung Ha ^b   Chung, Sungjin ^b   Choi, Bum Soon ^b   Yang, Chul Woo ^b   Kim, Yong Soo ^b   Chang, Yoon Sik ^b   Park, Cheol Whee ^b  

^a Hallym University   (South Korea)

^b The Catholic University of Korea   (South Korea)

Author keywords

Cardiac hypertrophy; Cinacalcet; Endothelial dysfunction; Oxidative stress

Indexed keywords

25 HYDROXYVITAMIN D; C REACTIVE PROTEIN; CALCIUM; CINACALCET; INTERCELLULAR ADHESION MOLECULE 1; ISOPROSTANE DERIVATIVE; NITRATE; NITRIC OXIDE; NITRITE; PARATHYROID HORMONE; PHOSPHORUS;

ADULT; ARTICLE; CALCIUM BLOOD LEVEL; CARDIOVASCULAR EFFECT; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIASTOLIC BLOOD PRESSURE; DIASTOLIC DYSFUNCTION; DRUG WITHDRAWAL; ENDOTHELIAL DYSFUNCTION; FEMALE; FOLLOW UP; HEART LEFT VENTRICLE MASS; HEART VENTRICLE HYPERTROPHY; HEMODIALYSIS; HUMAN; MALE; OPEN STUDY; OXIDATIVE STRESS; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; PROSPECTIVE PRICING; SECONDARY HYPERPARATHYROIDISM; TREATMENT DURATION;

CARDIOMEGALY; CROSS-OVER STUDIES; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; HYPERPARATHYROIDISM, SECONDARY; MALE; MIDDLE AGED; NAPHTHALENES; PROSPECTIVE STUDIES; RENAL DIALYSIS;

EID: 84874627903     PISSN: None     EISSN: 16602110     Source Type: Journal    
DOI: 10.1159/000347145     Document Type: Article

References (40)

1. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY: Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Eng J Med 2004; 351: 1296-1305.
2. Foley RN, Murray AM, Li S, Herzog CA, Mc-Bean AM, Eggers PW, Collins AJ: Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. J Am Soc Nephrol 2005; 16: 489-495.
3. Contreras G, Hu B, Astor BC, Greene T, Erlinger T, Kusek JW, Lipkowitz, M, Lewis JA, Randall OS, Hebert L, Wright JT Jr, Kendrick CA, Gassman J, Bakris G, Gopple JD, Appel LJ, African-American Study of Kidney Disease, and Hypertension Study Group: Malnutrition-inflammation modifies the relationship of cholesterol with cardiovascular disease. J Am Soc Nephrol 2010; 21: 2131-2142.
4. Udani S, Lazich I, Bakris GL: Epidemiology of hypertensive kidney disease. Nat Rev Nephrol 2011; 7: 434-444.
5. Bakris GL, Hart P, Ritz E: Beta blockers in the management of chronic kidney disease. Kidney Int 2006; 70: 905-1913.
6. Palmer SC, Navaneethan SD, Craig JC, Johnson DW, Tonelli M, Grag AX, Pellegrini F, Ravani P, Jardine M, Perkovic V, Graziano G, McGee R, Nicolucci A, Tognoni G, Strippoli GF: Meta-analysis: erythropoiesis-stimulating agents in patients with chronic kidney disease. Ann Intern Med 2010; 153: 23-33.
7. Del Vecchio L, Locatelli F, Carini M: What we know about oxidative stress in patients with chronic kidney disease on dialysis-clinical effects, potential treatment, and prevention. Semin Dial 2011; 24: 56-64.
8. Jourde-Chiche N, Dou L, Cerini C, Dignat-George F, Brunet P: Vascular incompetence in dialysis patients-protein-bound uremic toxins and endothelial dysfunction. Semin Dial 2011; 24: 327-337.
9. Hurska KA, Choi ET, Memon I, Davis TK, Mathew S: Cardiovascular risk in chronic kidney disease (CKD): the CKD-mineral bone disorder (CKD-MBD). Pediatr Nephrol 2010; 25; 76-778.
10. Raggi P, Chertow GM, Torres PU, Csiky B, Naso A, Nossuli K, Moustafa M, Goodman WG, Lopez N, Downey G, Dehmel B, Floege J: The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus lowdose vitamin D on vascular calcification in patients on hemodialysis. Nephrol Dial Transplant 2011; 26: 1327-1339.
11. KDIGO clinical practice guideline for diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl 2009; 113:S1-S130.
12. Block GA, Martin KJ, de Francisco ALM, Turner SA, Avram MM, Suranyi MG, Hercz G, Cunningham J, Abu-Alfa AK, Messa P, Coyne DW, Locatelli F, Cohen RM, Evenepoel P, Moe SM, Fournier A, Braun J, McCary LC, Zani VJ, Olson KA, Drueke TB, Goodman WG: Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 2004; 320: 1516-1525.
13. Block GA, Zaun D, Smits G, Persky M, Brillhart S, Nieman K, Liu J, St Peter WL: Cinacalcet hydrochloride treatment significantly improves all-cause and cardiovascular survival in a large cohort of hemodialysis patients. Kidney Int 2010; 78: 578-589.
14. Corretti MC, Anderson TJ, Benjamin EJ, Celermahjer D, Charbonneau F, Creager MA, Drexler H, Gerhard-Herman M, Herrington D, Vallance P, Vita J, Vogel R, International Brachial Artery Reactivity Task Force: Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactive Task Force. J Am Coll Cardiol 2002; 39: 257-265.
15. Sakane K, Miyoshi T, Doi M, Hirohata S, Kaji Y, Kamikawa S, Ogawa H, Hatanaka K, Kitawaki T, Kusachi S, Yamamoto K: Association of new arterial stiffness parameter, the cardio-ankle vascular index, with left ventricular diastolic function. J Atheroscler Thromb 2008; 15: 261-268.
16. Shan DJ, DeMore A, Kissol J, Weyman A: Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation 1978; 58: 1072-1083.
17. Foley RN, Parfrey PS, Samak MJ: Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998; 32(Suppl 3):S112-S119.
18. Olgaard K, Lewin E, Silver J: Calcimimetics, vitamin D and ADVANCE in the management of CKD-MBD. Nephrol Dial Transplant 2011; 26: 1117-1119.
19. London GM: Cardiovascular calcifications in uremic patients: clinical impact on cardiovascular function. J Am Soc Nephrol 2003; 14(suppl 4):S305-S309.
20. Wada T, McKee MD, Steitz S, Giachelli CM: Calcification of vascular smooth muscle cell cultures: inhibition by osteopontin. Cir Res 1999; 84: 166-178.
21. van de Stolpe A, van der Saag PT: Intercellular adhesion molecule-1. J Mol Med 1996; 74: 13-33.
22. Galkina E, Ley K: Leukocyte recruitment and vascular injury in diabetic nephropathy. J Am Soc Nephrol 2006; 17: 368-377.
23. Calfee CS, Eisner MD, Parsons PE, Thompson BT, Conner ER Jr, Matthay MA: Soluble intercellular adhesion molecule-1 and clinical outcomes in patients with acute lung injury. Intensive Care Med 2009; 35: 248-257.
24. Cai H, Harrision DG: Endothelial dysfunction in cardiovascular disease: the role of oxidant stress. Circ Res 2000; 87: 840-844.
25. Minuz P, Fava C, Lechi A: Lipid peroxidation, isoprostanes and vascular damage. Pharmacol Rep 2006; 58(suppl):S57-S68.
26. Janssen LJ: Isoprostanes and lung vascular pathology. Am J Respir Cell Mol Biol 2008; 39: 383-389.
27. Lawson C, Wolf S: ICAM-1 signaling in endothelial cells. Pharmacol Rep 2009; 61: 22-32.
28. Kado S, Nagata N: Circulating intercellular adhesion molecule-1, vascular cell adhesion molecule-1, and E-selectin in patients with type 2 diabetes mellitus. Diabetes Res Clin Prac 1999; 46: 143-148.
29. Wang AY, Lam CW, Wang M, Woo J, Chan IH, Lui SF, Sanderson JE, Li PK: Circulating soluble vascular cell adhesion molecule 1: relationships with residual renal function, cardiac hypertrophy, and outcome of peritoneal dialysis patients. Am J Kidney Dis 2005; 5: 715-729.
30. Horstman LL, Jy W, Jimenez JJ, Ahn YS: Endothelial microparticles as markers of endothelial dysfunction. Front Biosci 2004; 9: 1118-1135.
31. Vita JA: Endothelial function. Circulation 2011; 124: 906-912.
32. Endemann DH, Schiffrin EL: Endothelial dysfunction. J Am Soc Nephrol 2004; 15: 1983-1992.
33. Wever R, Boer P, Hijmering M, Stroes E, Verhaar M, Kastelein J, Versluis K, Lagerwerf F, van Rijn H, Koomans H, Ravelink T: Nitric oxide production is reduced in patients with chronic renal failure. Artherioscler Throm Vasc Biol 1999; 19: 1168-1172.
34. Navaneethan SD, Schold JD, Arrigain S, Jolly SE, Jain A, Schreiber MJ Jr, Simon JF, Srinivas TR, Nally JV Jr: Low 25-hydroxyvitamin D levels and mortality in non-dialysis-dependent CKD. Am J Kidney Dis 2011; 58: 536-543.
35. Pilz S, Iodice S, Zittermann A, Grant WB, Gandini S: Vitamin D status and mortality risk in CKD: a meta-analysis of prospective studies. Am J Kidney Dis 2011; 58: 374-382.
36. Wolf M, Shah A, Gutierrez O, Ankers E, Monroy M, Tamez H, Steele D, Chang Y, Camargo CA Jr, Tonelli M, Thadhani R: Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int 2007; 72: 1004-1013.
37. Wilkie M, Pontoriero G, Mocario F, Yaqoob M, Bouman K, Braun J, von Albertini B, Brink H, Msduell F, Graf H, Frazao JM, Bos WJ, Torregrosa V, Saha H, Reichel H, Zani V, Carter D, Messa P: Impact of vitamin D dose on biochemical parameters in patients with secondary hyperparathyroidism receiving cinacalcet. Nephron Clin Prac 2009; 112:c41-c50.
38. Abdullah HI, Pedraza PL, Hao S, Rodland KD, McGigg JC, Ferreni NR: NFAT regulates calcium-sensing receptor-mediated TNF production. Am J Physiol Renal Physiol 2006; 290:F1110-F1117.
39. Canaff L, Hendy GN: Calcium-sensing receptor gene transcription is up-regulated by the proinflammatory cytokine, interleukin-1beta. Role of the NF-kappaB pathway and kappaB elements. J Biol Chem 2005; 280: 14177-14188.
40. Canaff L, Zhou X, Hendy GN: The inflammatory cytokine, interleukin-6, up-regulates calcium-sensing receptor gene transcription via Stat1/3 and Sp1/3. J Biol Chem 2008; 283: 13586-13600.